Among 9 analysts covering Ignyta (NASDAQ:RXDX), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Ignyta has $38 highest and $1500 lowest target. $24.13’s average target is -10.13% below currents $26.85 stock price. Ignyta had 18 analyst reports since August 12, 2015 according to SRatingsIntel. The company was initiated on Tuesday, November 10 by Cantor Fitzgerald. Piper Jaffray maintained Ignyta, Inc. (NASDAQ:RXDX) on Wednesday, August 12 with “Overweight” rating. Jefferies initiated it with “Buy” rating and $18 target in Friday, October 23 report. Cantor Fitzgerald maintained Ignyta, Inc. (NASDAQ:RXDX) rating on Monday, July 10. Cantor Fitzgerald has “Buy” rating and $1500 target. Jefferies maintained the stock with “Buy” rating in Friday, October 20 report. The company was maintained on Sunday, June 4 by Cantor Fitzgerald. The stock of Ignyta, Inc. (NASDAQ:RXDX) earned “Overweight” rating by JP Morgan on Thursday, June 23. The stock of Ignyta, Inc. (NASDAQ:RXDX) earned “Buy” rating by Cantor Fitzgerald on Monday, October 26. The stock has “Outperform” rating by Credit Suisse on Tuesday, March 15. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”.
Among 2 analysts covering Hovnanian (NYSE:HOV), 0 have Buy rating, 2 Sell and 0 Hold. Therefore 0 are positive. Hovnanian had 4 analyst reports since September 10, 2015 according to SRatingsIntel. The rating was downgraded by JMP Securities on Thursday, January 12 to “Mkt Underperform”. M Partners downgraded the stock to “Sell” rating in Friday, December 22 report. The rating was maintained by M Partners on Thursday, September 10 with “Neutral”. On Friday, June 3 the stock rating was maintained by M Partners with “Neutral”. See Hovnanian Enterprises, Inc. (NYSE:HOV) latest ratings:
22/12/2017 Broker: M Partners Old Rating: Neutral New Rating: Sell Downgrade
The stock increased 72.67% or $11.3 during the last trading session, reaching $26.85. About 38.55M shares traded or 2004.86% up from the average. Ignyta, Inc. (NASDAQ:RXDX) has risen 14.24% since December 26, 2016 and is uptrending. It has underperformed by 2.46% the S&P500.
Investors sentiment decreased to 2.28 in 2017 Q3. Its down 0.68, from 2.96 in 2017Q2. It fall, as 14 investors sold Ignyta, Inc. shares while 18 reduced holdings. 35 funds opened positions while 38 raised stakes. 44.98 million shares or 5.65% more from 42.58 million shares in 2017Q2 were reported. Metropolitan Life Insur Co Ny holds 34,450 shares. Axa holds 0.02% of its portfolio in Ignyta, Inc. (NASDAQ:RXDX) for 446,298 shares. Barclays Public Limited Liability holds 26,109 shares or 0% of its portfolio. Tudor Invest Et Al accumulated 11,482 shares. Millennium Mngmt Lc has invested 0% in Ignyta, Inc. (NASDAQ:RXDX). Spark Investment Mngmt Llc holds 57,000 shares or 0.04% of its portfolio. 57,500 are held by J Goldman & Com L P. National Bank & Trust Of America Corporation De owns 7,980 shares for 0% of their portfolio. Citadel Advsrs Limited Liability Company owns 0% invested in Ignyta, Inc. (NASDAQ:RXDX) for 78,242 shares. Vanguard Group owns 1.97 million shares. 12,345 were accumulated by Trexquant Invest L P. Lombard Odier Asset Management (Usa) owns 500,000 shares. Ameritas stated it has 4,386 shares or 0% of all its holdings. California Pub Employees Retirement System has 0% invested in Ignyta, Inc. (NASDAQ:RXDX) for 61,800 shares. Invesco Limited owns 206,127 shares for 0% of their portfolio.
Analysts await Ignyta, Inc. (NASDAQ:RXDX) to report earnings on March, 13. They expect $-0.44 earnings per share, up 34.33% or $0.23 from last year’s $-0.67 per share. After $-0.51 actual earnings per share reported by Ignyta, Inc. for the previous quarter, Wall Street now forecasts -13.73% EPS growth.
Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. The company has market cap of $1.78 billion. The Company’s products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. It currently has negative earnings.
Hovnanian Enterprises, Inc. designs, constructs, markets, and sells residential homes in the United States. The company has market cap of $416.83 million. It constructs single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes. It currently has negative earnings. The firm markets its build homes for first-time buyers, first-time and second-time move-up buyers, luxury buyers, active lifestyle buyers, and empty nesters in 167 communities in 33 markets.